212 related articles for article (PubMed ID: 15240550)
1. Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells.
Katano K; Safaei R; Samimi G; Holzer A; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(13):4578-88. PubMed ID: 15240550
[TBL] [Abstract][Full Text] [Related]
2. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells.
Safaei R; Katano K; Larson BJ; Samimi G; Holzer AK; Naerdemann W; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):756-67. PubMed ID: 15701866
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
[TBL] [Abstract][Full Text] [Related]
4. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Buss I; Reedijk J; Jaehde U
BMC Cancer; 2008 Jun; 8():175. PubMed ID: 18565219
[TBL] [Abstract][Full Text] [Related]
5. Cross-resistance to cisplatin in cells with acquired resistance to copper.
Safaei R; Katano K; Samimi G; Naerdemann W; Stevenson JL; Rochdi M; Howell SB
Cancer Chemother Pharmacol; 2004 Mar; 53(3):239-46. PubMed ID: 14648017
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.
Samimi G; Katano K; Holzer AK; Safaei R; Howell SB
Mol Pharmacol; 2004 Jul; 66(1):25-32. PubMed ID: 15213293
[TBL] [Abstract][Full Text] [Related]
8. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells.
Katano K; Safaei R; Samimi G; Holzer A; Rochdi M; Howell SB
Mol Pharmacol; 2003 Aug; 64(2):466-73. PubMed ID: 12869652
[TBL] [Abstract][Full Text] [Related]
9. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.
Katano K; Kondo A; Safaei R; Holzer A; Samimi G; Mishima M; Kuo YM; Rochdi M; Howell SB
Cancer Res; 2002 Nov; 62(22):6559-65. PubMed ID: 12438251
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.
Holzer AK; Katano K; Klomp LW; Howell SB
Clin Cancer Res; 2004 Oct; 10(19):6744-9. PubMed ID: 15475465
[TBL] [Abstract][Full Text] [Related]
11. Transport of cisplatin by the copper efflux transporter ATP7B.
Safaei R; Otani S; Larson BJ; Rasmussen ML; Howell SB
Mol Pharmacol; 2008 Feb; 73(2):461-8. PubMed ID: 17978167
[TBL] [Abstract][Full Text] [Related]
12. Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([[trans-PtCl(NH3)(2)]2mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis.
Kabolizadeh P; Ryan J; Farrell N
Biochem Pharmacol; 2007 May; 73(9):1270-9. PubMed ID: 17234160
[TBL] [Abstract][Full Text] [Related]
13. Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug.
Leonhardt K; Gebhardt R; Mössner J; Lutsenko S; Huster D
J Biol Chem; 2009 Mar; 284(12):7793-802. PubMed ID: 19141620
[TBL] [Abstract][Full Text] [Related]
14. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy.
Nakayama K; Kanzaki A; Terada K; Mutoh M; Ogawa K; Sugiyama T; Takenoshita S; Itoh K; Yaegashi N; Miyazaki K; Neamati N; Takebayashi Y
Clin Cancer Res; 2004 Apr; 10(8):2804-11. PubMed ID: 15102688
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK
Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na+,K+-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B.
Ahmed Z; Deyama Y; Yoshimura Y; Suzuki K
Cancer Chemother Pharmacol; 2009 Mar; 63(4):643-50. PubMed ID: 18545997
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B.
Dmitriev OY
Biochem Cell Biol; 2011 Apr; 89(2):138-47. PubMed ID: 21455266
[TBL] [Abstract][Full Text] [Related]
19. ATP7B antisense oligodeoxynucleotides increase the cisplatin sensitivity of human ovarian cancer cell line SKOV3ipl.
Xu W; Cai B; Chen JL; Li LX; Zhang JR; Sun YY; Wan XP
Int J Gynecol Cancer; 2008; 18(4):718-22. PubMed ID: 17944925
[TBL] [Abstract][Full Text] [Related]
20. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP.
Nakayama K; Kanzaki A; Ogawa K; Miyazaki K; Neamati N; Takebayashi Y
Int J Cancer; 2002 Oct; 101(5):488-95. PubMed ID: 12216079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
